secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-103126
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel reports Q4 2025 net loss of $29.5M; cash $119.7M; plans BLA for aglatimagene in Q4 2026
--------------------------------------------------------------------------------

- Net loss Q4 2025: $29.5M vs $14.1M Q4 2024; full year net loss $38.2M vs $55.2M (2024).
- Cash $119.7M at Dec 31, 2025; plus $93.5M net from Feb 2026 offering; runway into Q1 2028.
- Entered $130M term loan with Trinity Capital; $50M drawn; $100M royalty deal with RTW contingent on FDA approval.
- Plan to initiate pivotal phase 3 trial of aglatimagene in NSCLC in Q2 2026; BLA submission for prostate cancer in Q4 2026.
- FDA cleared IND for linoserpaturev in recurrent high-grade glioma; mature OS data expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/0001193125-26-103126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/cadl-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-103126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer